Tanium Converge Travels to London and Paris
Tanium, the industry’s only provider of converged endpoint management (XEM), today announced the beginning of the Converge World Tour 2023, a six-city series of its global user conference. The kickoff event in London will be held Tuesday, 18th April, at the London Landmark Hotel, with a show at the Campus Cyber, Paris to follow on Thursday where Tanium will showcase its innovation spotlight, including its product roadmap and future enhancements to the XEM platform.
Converge is Tanium’s flagship event that brings together industry specialists, peers, and partners to share strategies for leveraging converged endpoint management (XEM) to improve organizational cybersecurity readiness and response. There’s no better opportunity for IT and security practitioners to discover new ways of driving value to their boards and accelerating business initiatives than to gain outside perspectives and hear first-hand experiences from those on the frontline of the cyber landscape.
“Tanium’s commitment is first, last, and always to our customers, and we are grateful to have such a strong and extensive partner ecosystem that is equally committed to maximizing the value our customers achieve from their investments in Tanium,” said Steve Daheb, chief marketing officer at Tanium. “Join us in Paris and London to see why Forrester reports Tanium driving ROI of more than 200% for customers, why eight of top 10 global financial institutions and seven of the top 10 global retailers trust Tanium to maximize their ROI and simplify their technology environments while defending their organizations against emerging threats and expanding their knowledge of managing risk, securing technology, and unlocking innovation at scale from a single intuitive platform.”
Join Tanium for a dynamic keynote experience, featuring top executives and industry experts who will enable you to:
- Glimpse into the future with Tanium—including the global unveiling of a new offering designed to improve overall work productivity, increase employee satisfaction, and lower IT support costs
- Understand the use and benefits of XEM with category creator Steve Daheb
- Gain insights from an intimate fireside chat with customer success champion Charles Ross
- Explore the many ways Microsoft and Tanium work better together to improve cyber resilience with partner facilitator Mike Fiorina
- Get a firsthand look at real customer successes with a panel featuring Aviva and Fraser’s Group and partner enablement executive Todd Palmer
- Participate in peer-based breakout sessions across executive-, technical-, and partner-focused tracks
WHO : IT and security professionals from across Europe; Tanium’s newly appointed CEO, Dan Streetman, and members of his executive team; Forrester analyst Andrew Hewitt; Frasers Group’s Matthew Wilmot; Aviva’s Marc Hasketh-Boston; and Tanium customers and partners that include EY, PwC, Armadillo Managed Services, Computacenter, SCC, EndpointX, Pointwire, BlueTrusty, Capgemini, Cegedim, DOUNYX, EY, I-TRACING, Orange Cyberdefense, and more
WHAT : Tanium Converge London and Tanium Converge Paris, featuring spotlights on current trends, industry best practices, expert-led sessions, breakout discussions, and hands-on labs
WHER E: The Landmark London Hotel and the Campus Cyber in Paris–La Defense
WHEN : Tuesday, 18th April 2023 (London) and Thursday, 20th April (Paris)
HOW : The shows are sold out, but you can still register to secure your place on the waitlist or join us for mainstage public sessions on demand by signing up for the London show or the Paris event. We look forward to seeing you there!
About Tanium
Tanium, the industry’s only provider of converged endpoint management (XEM), is the reference platform of choice to manage complex security and technology environments. Only Tanium unifies teams and workflows and protects every endpoint from cyber threats by integrating IT, Compliance, Security, and Risk into a single platform that delivers comprehensive visibility across devices, a unified set of controls, and a common taxonomy for a single shared purpose: to protect critical information and infrastructure at scale. Tanium has been named to the Forbes Cloud 100 list for seven consecutive years and ranks on Fortune’s list of the Best Large Workplaces in Technology. In fact, more than half of the Fortune 100 and the U.S. armed forces trust Tanium to protect people; defend data; secure systems; and see and control every endpoint, team, and workflow everywhere. That’s the power of certainty. Visit www.tanium.com and follow us on LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005318/en/
Contact information
Lindsey Lockhart
Tanium PR
press@tanium.com
+ 1 214.562.1521
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
